Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA.
It was previously shown that i.p. administration of the alpha 2-adrenergic antagonist yohimbine increased the magnitude of the acoustic startle response in rats. The purpose of the present study was to determine possible central noradrenergic involvement in yohimbine's effect on startle. Pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromo-benzylamine (DSP4; 50 mg/kg, i.p.; 1-2 days before testing) completely blocked the excitatory effect of yohimbine on startle. DSP4 reduced forebrain and spinal cord NE levels by 47% and 56%, respectively, without affecting forebrain or spinal serotonin (5-HT), or forebrain dopamine (DA). Pretreatment with the NE reuptake blocker desmethylimipramine (DMI; 20 mg/kg, i.p.; 30 min before DSP4) prevented the ability of DSP4 to block the yohimbine effect. DMI partially reversed the NE-depleting effects of DSP4. Neither bilateral adrenalectomy nor intravenously administered 6-hydroxydopamine (6-OHDA; 20 mg/kg; 1-2 days before testing) altered the excitatory effect of yohimbine, indicating that peripheral NE is not involved. 6-OHDA (2 X 200 micrograms) injected into the lateral ventricles blocked yohimbine's effect, and depleted NE by 95% (spinal cord) and 86% (forebrain), without affecting 5-HT in either region. 6-OHDA also depleted forebrain DA levels by 49%. Finally, intrathecal administration of 6-OHDA (20 micrograms; 14 days before testing) into the subarachnoid space of the lumbar spinal cord blocked the excitatory effect of yohimbine, and produced an extensive (94%) depletion of spinal cord NE. Intrathecal 6-OHDA did not alter spinal levels of 5-HT or forebrain levels of NE, 5-HT or DA. In summary, these data indicate that central descending NE neurons are necessary for yohimbine's excitatory effect on startle.
D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D009434:Neural Pathways / Q000187:drug effects; D009638:Norepinephrine / Q000502:physiology*; D016627:Oxidopamine; D051381:Rats; D011919:Rats, Inbred Strains; D013216:Reflex, Startle / Q000187:drug effects* / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects* / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology*
D001596:Benzylamines; D006892:Hydroxydopamines; D015016:Yohimbine; D016627:Oxidopamine; C012102:DSP 4; D009638:Norepinephrine